Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; December 2022, Vol. 400 Issue: 10367 p1927-1937, 11p
- Subject
- Language
- ISSN
- 01406736; 1474547X